CYP3A4*22is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen

Evaluation of Tamoxifen and Metabolites by LC-MS/MS and HPLC Methods

(2016) D.D. Heath et al.   BRITISH JOURNAL OF BIOMEDICAL SCIENCE

Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N -desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots—Development, validation and clinical application during breast cancer adjuvant therapy

(2015) Marina Venzon Antunes et al.   TALANTA

Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care

(2014) N. G. L. Jager et al.   BREAST CANCER RESEARCH AND TREATMENT

Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen

(2014) Rob ter Heine et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Distribution of CYP2D6 Alleles and Phenotypes in the Brazilian Population

(2014) Deise C. Friedrich et al.   PLoS One

CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy

(2013) Wendy A. Teft et al.   BREAST CANCER RESEARCH AND TREATMENT

Association betweenCYP2D6genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis

(2013) Jin-A Jung et al.   PHARMACOGENOMICS

Interplay between vitamin D and the drug metabolizing enzyme CYP3A4

(2012) Zhican Wang et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Endoxifen Levels and Its Association With CYP2D6 Genotype and Phenotype

(2012) Marina V. Antunes et al.   THERAPEUTIC DRUG MONITORING

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

(2011) T E Mürdter et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes

(2011) L Madlensky et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenomics of CYP2D6: Molecular Genetics, Interethnic Differences and Clinical Importance

(2011) Lay Kek Teh et al.   Drug Metabolism and Pharmacokinetics

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

(2011) William J. Irvin et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients

(2011) Laure Elens et al.   PHARMACOGENOMICS

Pharmacogenetics and forensic toxicology

(2010) Frank Musshoff et al.   FORENSIC SCIENCE INTERNATIONAL

Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients

(2010) Silvana Borges et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

(2010) D Wang et al.   PHARMACOGENOMICS JOURNAL

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users

(2009) Monique J. Bijl et al.   BREAST CANCER RESEARCH AND TREATMENT

Pharmacogenomics of Tamoxifen Therapy

(2009) H. Brauch et al.   CLINICAL CHEMISTRY

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

(2009) Werner Schroth   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry

(2009) S.F. Teunissen et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Molecular diversity at theCYP2D6locus in healthy and schizophrenic southern Brazilians

(2009) Fabiana B Kohlrausch et al.   PHARMACOGENOMICS